- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
| Current Portfolio | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
CT – 1119 (CAR-Monocyte)Discovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: GPC3+ Solid TumorsDiscovery | Preclinical | Phase 1 |
|||
In Vivo CAR-Macrophage: Oncology TargetsDiscovery | Preclinical | Phase 1 |
|||
CT-2401 (Liver Fibrosis)Discovery | Preclinical | Phase 1 |
|||
Autoimmune DiseaseDiscovery | Preclinical | Phase 1 |
With our proprietary platform, we see an opportunity for:
Hear from CEO Steven Kelly on the promise and potential of Carisma’s proprietary platform.
With decades of experience in biotechnology and pharma, our dedicated team of top scientists and industry leaders are focused on developing a differentiated kind of cell therapy platform, addressing key challenges that remain unsolved.
Thanks to a network of expert advisors and our close collaboration with the University of Pennsylvania, we are continuing to advance targeted treatments for those tackling challenges associated with cancer every day.
See how the power of macrophages is harnessed to make life-changing progress.
Stay up to date with news, announcements, and more, by seeing our latest press releases and media coverage.
Our team is growing, and we want you to be a part of it. Be sure to check out our latest job openings.
If you’re dedicated to cutting edge science in healthcare, we want to hear from you.
Join Our Team